RIAS
CTMX icon

Rachor Investment Advisory Services’s CytomX Therapeutics CTMX Stock Holding History

Rachor Investment Advisory Services’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-175
Closed -$823 – 261
2026
Q1 		$823 Buy
+175
New +$888 ﹤0.01% 334

Other funds holding CTMX

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
AGP
Aspire Growth Partners Miromar Lakes, Florida $172M AUM 33.61% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Rachor Investment Advisory Services's CTMX Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 175 shares — an estimated $823 sold.

Rachor Investment Advisory Services first reported a position in CTMX in Q1 2026 and held it in 1 quarter. The position peaked at $823 in Q1 2026. 36 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 175 CytomX Therapeutics shares in Q2 2026, an estimated $823.
  • Rachor Investment Advisory Services first reported a position in CytomX Therapeutics in Q1 2026 and held it in 1 quarter.
  • Rachor Investment Advisory Services's CytomX Therapeutics position peaked at $823 in Q1 2026.
  • 36 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.